MaxCyte, Inc. Filing of Form 10-Q (0855Z)
May 11 2023 - 2:22AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 0855Z
MaxCyte, Inc.
11 May 2023
MaxCyte announces filing of Form 10-Q for the quarterly period
ended March 31, 2023
ROCKVILLE, MD, May 11, 2023 - MaxCyte, Inc., (NASDAQ: MXCT; LSE:
MXCT), a leading, cell-engineering focused company providing
enabling platform technologies to advance the discovery,
development, and commercialization of next-generation cell
therapeutics and to support innovative, cell-based research, today
announced that it has filed a Form 10-Q with the SEC for the
quarterly period ended March 31, 2023.
A copy of the Form 10-Q is available to view on the SEC's
website at www.sec.gov and has also been posted to the "SEC
filings" page of the Company's website,
https://investors.maxcyte.com/ .
About MaxCyte
At MaxCyte, we pursue cell engineering excellence to maximize
the potential of cells to improve patients' lives. We have spent
more than 20 years honing our expertise by building best-in-class
platforms, perfecting the art of the transfection workflow, and
venturing beyond today's processes to innovate tomorrow's
solutions. Our ExPERT(TM) platform, which is based on our Flow
Electroporation(R) technology, has been designed to support the
rapidly expanding cell therapy market and can be utilized across
the continuum of the high-growth cell therapy sector, from
discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx(TM), STx(TM), GTx(TM)
and VLx(TM); a portfolio of proprietary related processing
assemblies or disposables; and software protocols, all supported by
a robust worldwide intellectual property portfolio. By providing
our partners with the right technology, as well as technical and
regulatory support, we aim to guide them on their journey to
transform human health. Learn more at maxcyte.com and follow us on
Twitter and LinkedIn .
MaxCyte Contacts:
US IR Adviser +1 415-937-5400
Gilmartin Group ir@maxcyte.com
David Deuchler, CFA
Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden +44 (0)20 7886 2500
UK IR Adviser
Consilium Strategic Communications +44 (0)203 709 5700
Mary-Jane Elliott maxcyte@consilium-comms.com
Chris Welsh
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCNKDBBABKKDPD
(END) Dow Jones Newswires
May 11, 2023 02:22 ET (06:22 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024